Figure 4
Enhanced prediction power of iMethyl-liquid by probe weighting. (a–c) Survival analysis between the methylation-high and -low group based on the average methylation values from iMethyl-liquid of our lung cancer samples (upper) and breast cancer samples (lower) with (a) no weighting, (b) weighting by iMethyl-liquid of a different cancer type, and (c) weighting by iMethyl-tissue of the same cancer type. (d–e) Prediction power for the clinical outcome of ICB therapy comparing different weighting schemes for (d) lung cancer iMethyl-liquid and (e) breast cancer iMethyl-liquid. Performance was estimated by 5000 trials of bootstrapping of individual patient samples. In each sampling, the P value from the survival analysis was obtained. The resulting 5000 P values for different weighting schemes were compared by the Wilcoxon signed-rank test (P value of **** < 1 × 10–4).
